“…These developments in technology, disease treatment and management have allowed HSCT to become commonplace in contemporary medicine (Cutler & Antin, 2005;Ezzone, 2009;Saria & Gosselin-Acomb, 2007;Schmit-Pokorny, 2009;Shivnan, Shelton, & Onners, 1996) with approximately 50,000 transplant being undertaken annually worldwide (Ferrara et al, 2007). In Manitoba, over HSCT has been used for numerous years primarily for the treatment of haematological malignancies such as, leukemias, lymphomas and multiple myeloma.…”